| Intensive statin therapy in coronary artery disease: is lower cholesterol better and safe? | |
| | |
MedLine Citation:
|
PMID: 19371188 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Primary- and secondary-prevention trials involving subjects with or at risk for coronary artery disease have previously demonstrated a beneficial effect of conventional-dose statin therapy. Recent trials of high-dose statin therapy in subjects with stable coronary disease or acute coronary syndromes have yielded conflicting results. The aim of this narrative article is to provide a critical and up-to-date summary of the findings of clinical trials of intensive statin therapy, including a brief overview of the safety and efficacy of such treatments. |
| | |
Authors:
|
Sreenivasa R K Seshasai; Kausik K Ray |
Related Documents
:
|
10653268 - Odynophagia in a woman with known coronary artery disease and ischemia on electrocardio... 11096528 - Kawasaki disease. 7639338 - Infrequency of cytomegalovirus genome in coronary arteriopathy of human heart allografts. 14681238 - Pro-thrombotic state induced by post-translational modification of fibrinogen by reacti... 15213088 - Modified elephant trunk technique for distal reconstruction of ragged descending thorac... 34308 - Spontaneous non-aneurysmal rupture of the renal pedicle artery due to acute vasculitis ... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Future cardiology Volume: 5 ISSN: 1744-8298 ISO Abbreviation: Future Cardiol Publication Date: 2009 Mar |
Date Detail:
|
Created Date: 2009-04-17 Completed Date: 2009-07-30 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101239345 Medline TA: Future Cardiol Country: England |
Other Details:
|
Languages: eng Pagination: 129-39 Citation Subset: IM |
Affiliation:
|
Molecular Epidemiology Unit, Strangeways Research Laboratory, Worts Causeway, Cambridge, CB1 8RN, UK. srk36@medschl.cam.ac.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cholesterol
/
blood* Coronary Artery Disease / blood, drug therapy* Dose-Response Relationship, Drug Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage, therapeutic use* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 57-88-5/Cholesterol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Noninvasive assessment of myocardial ischemia in the future: fusion of anatomical and functional ima...
Next Document: Drug-eluting stents: a comprehensive appraisal.